KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Vertex Pharmaceuticals (VRTX) Enterprise Value (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Enterprise Value data on record, last reported at -$5.1 billion in Q4 2025.

  • For Q4 2025, Enterprise Value rose 16.86% year-over-year to -$5.1 billion; the TTM value through Dec 2025 reached -$5.1 billion, up 16.86%, while the annual FY2025 figure was -$5.1 billion, 16.86% up from the prior year.
  • Enterprise Value reached -$5.1 billion in Q4 2025 per VRTX's latest filing, down from -$4.9 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$1.5 billion in Q1 2025 and bottomed at -$11.9 billion in Q3 2023.
  • Average Enterprise Value over 5 years is -$8.0 billion, with a median of -$7.5 billion recorded in 2021.
  • Peak YoY movement for Enterprise Value: tumbled 65.23% in 2021, then soared 85.01% in 2025.
  • A 5-year view of Enterprise Value shows it stood at -$7.5 billion in 2021, then crashed by 43.14% to -$10.8 billion in 2022, then fell by 4.08% to -$11.2 billion in 2023, then soared by 45.48% to -$6.1 billion in 2024, then rose by 16.86% to -$5.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$5.1 billion in Q4 2025, -$4.9 billion in Q3 2025, and -$1.5 billion in Q1 2025.